Turnaround
PANDION’s Insolvency Ripple Effect: Eleven Project Vehicles File as the Group’s Financial Architecture Unravels
The cascading collapse at PANDION has now reached deep into the operational heart of the Cologne-based property developer. Late last...
Nel ASA’s Backlog Grows, But the Ledger Tells a Bleaker Story
The gap between Nel ASA's order intake and its bottom line has become the defining narrative for the Norwegian hydrogen...
Thyssenkrupp’s Rally Rests on a Delicate Balance of Breakup Hopes and China Tailwinds
The arithmetic is beguilingly simple. Add up the value of Thyssenkrupp's parts, and the conglomerate's market capitalization of €8.07 billion...
WiseTech Global Rebounds as Investors Weigh Cost Cuts Against Regulatory Storm
The whiplash in WiseTech Global's share price this week tells two very different stories about the Australian logistics software group....
Thyssenkrupp’s Mixed Signals: Submarine Orders Soar While Green Hydrogen Ambitions Cool
The industrial conglomerate's latest guidance update tells two very different stories — one of military shipbuilding momentum, the other of...
Plug Power’s Balancing Act: Property Sales Fund the Present While Australia’s Hydrogen Hub Points to the Future
When Plug Power releases its second-quarter results after the US market close on Monday, management will face an audience torn...
Atlassian’s €128.80 Spike: A Profitability Inflection Point Arrives Just as Growth Slows
The software maker that spent years convincing investors to look past red ink finally handed them a reason to cheer....
Siemens Energy’s AI-Fueled Boom Masks a Structural Question That Won’t Wait
The numbers tell a story of a company reborn. Siemens Energy's third-quarter results, published Wednesday, show a business that has...
Thyssenkrupp’s Unbundling Machine Grinds Toward an October Milestone
The arithmetic of corporate breakups is rarely this clean. Thyssenkrupp's shares have climbed roughly a third since January, and the...
Spero Therapeutics Pivots Away From Infectious Disease as Shares Sink to Historic Lows
The market has delivered a brutal verdict on Spero Therapeutics' corporate reinvention. Shares in the biotech group have tumbled roughly...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
